Effects of psychotropic switches on weight change: a prospective cohort study

INTRODUCTION: Many psychotropic drugs can induce weight gain with differences in their metabolic risk profiles (i.e. high, medium or low-risk). OBJECTIVES: To compare the weight evolution of patients switching versus patients keeping their psychotropic drugs with different risk-profiles. METHODS: Data for patients switching or keeping the same drug were obtained from the Psyclin (from 2007 to 2015) and Psymetab (2007- 2019) cohort studies, conducted at the Lausanne University Hospital, Switzerland. Patients either switched from a high to a low-risk, a high to a medium-risk, a medium to a low-risk drug, or for a drug with the same risk category. Patients not switching either kept a high, medium or low-risk drug. The evolution of weight is currently being analyzed using a linear mixed-effect model. RESULTS: Preliminary results showed that switching from a high to low-risk molecule had the strongest impact on weight changes. The analysis being ongoing, the quantitative results will be presented at the congress. CONCLUSIONS: Switching from a high-risk to a low-risk molecule is likely to have the strongest impact on weight changes. DISCLOSURE: No significant relationships.